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Abstract
Background:  Chondromyxoid fibromas (CMFs) are rare benign chondroid/myxoid matrix-
producing tumors that occur in metaphyses of long tubular bones, and very rarely in small bones
of hands and feet. Flat bone involvement is even more uncommon. Prior cytogenetic analyses have
identified complex abnormalities involving chromosome 6 in the majority of cases.
Methods: A search for CMF over an 8-year period (1999–2006) from the surgical pathology files
of our institution yielded 16 cases. Four cases occurred in relatively unusual regions, three from
the small bones of distal extremities and one from the rib. The rib lesion wassubmitted
forroutinecytogenetic analysis.
Results: Radiographic studies revealed that all four lesions were well-defined expansile radiolucent
lesions which expanded the bony cortices with lobulated margins, sclerotic rim, septation, and no
calcification. Morphologically, all four lesions showed typical features of CMF and had low
proliferative index with Ki-67. Cytogenetic analysis on the rib lesion revealed a novel chromosomal
translocation, t(1;5)(p13;p13). None of the four patients had a recurrence after a mean duration of
follow-up of 24 months.
Conclusion: CMF originating in unusual locations should be distinguished from chondrosarcomas,
especially on small biopsies, and should be included in the differential diagnosis. As previously noted
in the literature, the cells can be positive for actin but unlike conventional chondroid neoplasms
can be negative for S-100. To our knowledge, this is the first report describing a novel
chromosomal translocation, t(1;5)(p13;p13) in CMF.
Background
Chondromyxoid fibroma (CMF) is a rare, peculiar, and
benign primary bone tumor that show heterogeneous
cytomorphology with a spectrum of chondroid, fibroblas-
tic, and myxoid areas. CMF was originally described and
distinguished from other aggressive bone tumors by Jaffe
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and Lichtenstein in 1948 [1]. It usually presents in the sec-
ond to third decade, has a male to female ratio of 2 to 1,
and is found most often in the metaphysis around the
knee in the proximal tibia, proximal fibula or distal femur
[2-9]. CMF is thought to be one of the least common bone
tumors, representing less than 1% of all primary bone
neoplasms and less than 2% of benign bone neoplasms
[2,4,10,11]. It occurs most frequently in young adults dur-
ing the second or third decades of life and is more fre-
quent in males than females [2-9]. Although CMF may
involve any bone of the skeleton, it is most commonly
found in the metaphyses of major long tubular bones of
the lower extremities, particularly around the knee joint
[2,4,7-9,12]. CMF has been described as occurring in the
apophyses or intracortically [13-17]. Approximately 25%
of lesions occur in flat bones, such as the ilium, metatar-
sals, vertebrae, skull, facial bones, and ribs [2,4,7-9,12].
Lesions in the ribs are extremely rare with only nine
reported cases in the English language medical literature
[7,18-22]. Clinically, CMF is slow growing and are com-
monly asymptomatic lesions that are discovered inciden-
tally on radiography [9]. When symptomatic, their clinical
presentation is usually chronic local pain (85%), swelling
(65%), restriction of motion and, more rarely, pathologi-
cal fracture [8,11]. The previously described typical radio-
logical features of long bone CMF is a well-defined
metaphyseal lytic lesion with a sclerotic rim, septation,
and no calcification [23,24]. Cortical expansion and focal
destruction may be observed sometimes, but generally the
appearances are of a benign lesion. Calcification and int-
ralesional opacities are uncommon and occurs in about
2% of lesions [23,24].
The classic histological features of CMF are lobules of
spindle-shaped or stellate cells with abundant myxoid or
chondroid intercellular material separated by zones of
more cellular tissue rich in spindle-shaped or round cells
with a varying number of multinucleated giant cells of dif-
ferent sizes [4,7-10]. Mitoses are exceptionally rare in
CMF [4,7-10]. Although it has been suggested that
enlarged, pleomorphic nuclei and a prominent mucinous
or myxoid component may indicate a higher recurrence
rate, histological features are probably not predictive of
recurrence [4,7-10]. Recurrence may be more frequent in
younger patients [4,8-10]. The identified predisposing fac-
tors accounting for the recurrence of CMF are its friable
nature resulting in incomplete removal [7,24]. Despite
occasional nuclear atypia and local recurrences, CMF is a
benign neoplasm and there have been no reports of
metastases. Curettage and concurrent bone grafting with
allograft bone or polymethylmethacrylate (PMMA)
resulted in a much lower recurrence rate than curettage
alone, whereas tumors treated by excision did not recur
[4,7-10,24]. Local recurrence of CMF following surgery is
well recognized and occurs in 3–22% of cases [7-10,25].
Malignant transformation of CMF is a rare event and is
reported to be 1–2% [8,25]. Two cases of malignant trans-
formation of CMF after irradiation have been reported
[8,9]. Adequate surgical ablation is curative.
The precise histogenesis of CMF is uncertain and is a mat-
ter of continuing speculation. A cartilaginous origin, orig-
inally proposed on morphological grounds, was
subsequently supported by ultrastructural studies and the
demonstration of S-100 protein by immunohistochemi-
cal studies [5,26-28]. Neilsen [27] showed myofibroblas-
tic, myochondroblastic, and chondrocytic differentiation
in CMF on the basis of variable immunostaining for
smooth muscle actin (SMA) and S-100 protein. Therefore,
it has been suggested on the basis of immunohistochemi-
cal studies that CMF resembles chondroblastoma, partic-
ularly in relation to the finding of S-100
immunoreactivity; however other types of tumors have
similar findings [5,26-28]. Additionally, osteocalcin is
present in greater than 50% of CMFs, and in other bone
and cartilage tumors, especially chondroblastomas [5].
Karyotypes of fifteen cases of CMF are reported in the Eng-
lish language medical literature, with twelve cases report-
ing non-random clonal abnormalities involving
chromosome 6 [29-38]. In the present report, we describe
the clinical, cytological, histological, immunohistochem-
ical and cytogenetic features of four cases of CMF that
arose in the rib, finger and foot.
Methods
Sixteen cases of CMF were retrieved from the surgical
pathology files of our institution over an 8-year (1999–
2006) period. Four of these 16 cases occurred in relatively
unusual regions, including one from metatarsal, two from
phalanges, and one from the rib. Clinical information
including radiological features and follow-up informa-
tion was obtained and reviewed for these four cases of
CMF at unusual sites. Available original histologic and
cytologic slides on all four cases were retrieved and
reviewed by two of the authors (AVP and UNMR) who
concurred on the diagnoses. Immunohistochemical stain-
ing for a panel of antibodies (Table 1) was performed on
histologic sections of each of the four cases using standard
protocols with a 3-step avidin-biotin-streptavidin proce-
dure. A computer tomography (CT)-guided fine needle
aspiration (FNA) biopsy of the right anterior second rib
mass (case no. 2) was done prior to the subsequent defin-
itive resection, and immunocytochemical staining for S-
100 and Ki-67 was performed for this case. For all immu-
nohistochemical and immunocytochemical analyses,
appropriate negative and positive controls were included.
A fresh unfixed tumor sample of the resected right anterior
second rib mass (case no. 2) was submitted to the Pitts-
burgh Cytogenetics Laboratory in RPMI tissue cultureDiagnostic Pathology 2007, 2:44 http://www.diagnosticpathology.org/content/2/1/44
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medium for cytogenetic analysis during the intraoperative
evaluation for negative resection margins, since a diagno-
sis of CMF was favored for the prior CT-guided FNA
biopsy. The tumor tissue was treated with collagenase to
enzymatically dissociate cells, which were then cultured
for 7 to 9 days. Metaphase cells were harvested and chro-
mosomes were GTG-banded using standard procedures.
Results
Clinical and radiological features
The clinical and radiological features of the four cases of
CMF are summarized in Table 2. The patients ranged in
age from 14 to 55 years (mean, 32.25 years). Three
patients were female and one was male. A right-sided pre-
ponderance was observed (3/4 cases). Two cases each pre-
sented before and after skeletal maturity. The anatomical
distribution of the four lesions was anterior second rib,
proximal phalanx of fifth toe, distal phalanx of fourth fin-
ger, and second metatarsal. The size of the lesions ranged
from 1.3 to 6.1 cm (mean, 2.85 cm). The duration of
symptoms prior to diagnosis ranged from 9 to 36 months
(mean, 16.75 months). Three cases presented with a pain-
ful lump and one with pain only. None of the lesions were
found incidentally by radiography. The typical radiologi-
cal features of a well-defined expansile radiolucent lesion
with scalloped or lobulated margins, a sclerotic rim, sep-
tation, and no calcification were observed in all four cases
of CMF (Figures 1 &2). Three patients with CMF of the
foot and hand underwent curettage along with bone graft-
ing using polymethylmethacrylate (PMMA). The patient
with CMF of the anterior right second rib underwent a
wide "enbloc" resection with chest wall reconstruction
using Gore-Tex patch. None of the four patients had a
recurrence after a mean duration of follow-up of 24
months.
Pathologic features
Macroscopic findings
The curetted and resected tumor tissue received from all
the four cases of CMF were expansile bone masses (Figure
Table 1: Antibodies used in the immunohistochemical study of three cases of chondromyxoid fibromas
Antibody Manufacturer Pretreatment Source; dilution
S-100 Ventana (Tucson, AZ) CCI; 30 mins; 37°C Mouse; prodilution
SMA Ventana (Tucson, AZ) CCI; 30 mins; 37°C Mouse; prodilution
AE1-AE3 Ventana (Tucson, AZ) Protease 1; 4 mins; 37°C mAb; prodilution
EMA DAKO (Carpinteria, CA) None mAb; 1:1000
CD34 Ventana (Tucson, AZ) CCI; 30 mins; 37°C Mouse; prodilution
Ki-67 Ventana (Tucson, AZ) CCI; 30 mins; 37°C Mouse; prodilution
Table 2: Clinical and radiological features of the three cases of chondromyxoid fibromas
Case 
no.
Age (years)/
sex/side
Anatomic site/
size
Clinical 
presentation/
duration
Radiologic findings Treatment Follow-up 
(months)
Surgery Bone grafting
1 14/F/R Proximal phalanx 
of fifth toe/1.3 cm
Painful lump/9 
months
Radiolucent lesion 
with scalloped and 
sclerotic borders, and 
no calcification
Curettage Yes, with PMMA 22, NR
2 43/F/R Anterior second 
rib/6.1 cm
Painful lump/3 
years
Radiolucent lesion 
with scalloped and 
sclerotic borders, and 
no calcification
Wide enbloc excision 
with complete 
resection, and Gore-
Tex patch chest wall 
reconstruction
No 27, NR
35 5 / M / L S e c o n d  
metatarsal/2.5 cm
Pain/1 year Radiolucent lesion 
with scalloped and 
sclerotic borders, and 
no calcification
Curettage Yes, with PMMA 39, NR
4 17/F/R Distal phalanx of 
fourth finger/1.5 
cm
Painful lump/10 
months
Radiolucent lesion 
with scalloped and 
sclerotic borders, and 
no calcification
Curettage Yes, with PMMA 8, NR
F, female; M, male; R, right; L, left; PMMA, polymethylmethacrylate; NR, no recurrence;Diagnostic Pathology 2007, 2:44 http://www.diagnosticpathology.org/content/2/1/44
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3A) with firm consistency, and their cut sections showed
distinct glistening, lobulated appearance, with bluish-
white color (Figure 3B).
Microscopic findings
Cytologic and histologic findings
CT-guided FNA of the second rib mass (case no. 2)
revealed a chondroid neoplasm with low Ki-67 prolifera-
tive marker index, and strongly suggested a diagnosis of
CMF. The histologic features of all the four resected and
curetted tumors were similar to that previously described
in the literature. The tumors were composed of lobules of
paucicellular pale blue myxoid matrix containing anasto-
mosing strands of spindle and stellate cells with bland
nuclei, finely dispersed chromatin, and inconspicuous
nucleoli (Figures 4A, 4B &4C). The periphery of the lob-
ules were often rimmed by hypercellular areas that con-
tained similar fusiform to spindle cells mingled with
variable numbers of osteocleast-like giant cells (Figure
4D). The nuclei of the stellate cells, especially those in the
peripheral areas, showed occasional atypia with enlarged
nuclei, coarsely clumped chromatin, and identifiable
nucleoli. No mitoses or areas of necrosis were identified.
Cells did not occur within lacunae, and no areas of micro-
scopic calcification were found in all four cases of CMF.
Immunohistochemical findings
The immunohistochemical staining patterns of the four
cases of CMF are presented in Table 3. S-100 protein was
negative in all four cases of CMF (0%; 0/4) [Figure 5A].
The other immunohistochemical markers that were nega-
tive in all four cases of CMF were AE1-AE3 (0%; 0/4) [Fig-
ure 5B], epithelial membrane antigen (EMA) [0%; 0/4],
and CD34 (0%; 0/4). Smooth muscle actin (SMA) was
positive in two of the four cases of CMF (50%; 2/4) [Fig-
ure 5C]. All four cases of CMF showed low proliferative
index with Ki-67 immunostaining of less than 5% of neo-
plastic cells [Figure 5D].
Cytogenetic findings
Twenty-one trypsin-Giemsa banded metaphase cells were
analyzed from 6, 7 and 8-day harvests of monolayer cell
cultures derived from the right second rib tumor (case no.
Computed tomography scan of chest (case no. 2) demon- strating a radiolucent lesion of the right anterior second rib  with cortical bubbling or blebbing, and without radiographic  evidence of an acute fracture, calcification or malignancy  (arrow) Figure 2
Computed tomography scan of chest (case no. 2) demon-
strating a radiolucent lesion of the right anterior second rib 
with cortical bubbling or blebbing, and without radiographic 
evidence of an acute fracture, calcification or malignancy 
(arrow). R indicates right side.
X-ray of the right foot (case no. 1) showing a radiolucent  lesion of the proximal metaphysis of the fifth proximal pha- lanx with scalloped and sclerotic borders, pronounced thin- ning of the medial and lateral cortices, and without  radiographic evidence of an acute fracture, calcification or  malignancy (arrow) Figure 1
X-ray of the right foot (case no. 1) showing a radiolucent 
lesion of the proximal metaphysis of the fifth proximal pha-
lanx with scalloped and sclerotic borders, pronounced thin-
ning of the medial and lateral cortices, and without 
radiographic evidence of an acute fracture, calcification or 
malignancy (arrow). R indicates the right side.Diagnostic Pathology 2007, 2:44 http://www.diagnosticpathology.org/content/2/1/44
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2). Three cells had an apparently normal female chromo-
some complement. Eighteen cells showed an abnormal
pseudodiploid clone with a clonal translocation between
the short arms of chromosomes 1 and 5 [46,XX,t(1;5)(p1
3;p13)] (Figure 6). Four of these eighteen cells had addi-
tional non-clonal single cell abnormalities. One cell each
had the following chromosome patterns: 46,X,del(X)(p1
0),t(1;5)(p13;p13); 46,XX,t(1;5)(p13;p13),t(17;19)(q
11.2;p11.2); 46,XX,der(1)(1qter→1p13::5p13→5pter),
der(5;6)(1pter→1p13::5p13→5q10::6q10→6qter),der(5;
6)(p10;q10); and 45,XX,t(1;5)(p13;p13)t(13;17)(q14;p1
3),-14. The overall karyotype results can be described by
the following International System for Human Cytoge-
netic Nomenclature (ISCN 2005): 46,XX,t(1;5)(p13;p13)
[18]/46,XX[3].
Discussion
The radiological and clinical presentation of all the four
cases of CMF in this study is similar to those in the avail-
able literature on CMF [3-5,9-11,23-25]. Between 15%
and 31% of cases of CMF have been reported to originate
in the foot and ankle, and the involvement of the small
bones of the feet by CMF has been reported as five times
more common than the involvement of the small bones
of the hands [2,4,7-9,12]. CMF has no specific radiologi-
Macroscopic findings of CMF of the resected right anterior  second rib (case no. 2) Figure 3
Macroscopic findings of CMF of the resected right anterior 
second rib (case no. 2). (A) Rib with expansile mass. (B) Cut 
section of expansile mass showing a distinct glistening, lobu-
lated appearance, with bluish-white color.
Histologic findings of CMF obtained from resected surgical  specimen (case no. 2) Figure 4
Histologic findings of CMF obtained from resected surgical 
specimen (case no. 2). (A) Well circumscribed lobules of 
loose chondroid and myxoid tissue delineated by hypercellu-
lar fibrous septae containing bland fibroblasts (H&E, ×4). (B) 
Characteristic zoned hypercellular areas with osteoclast-like 
giant cells surrounding chondroid and myxoid areas (H&E, 
×10). (C) Chondroid and myxoid matrix containing anasto-
mosing strands of spindle and stellate cells with bland nuclei, 
finely dispersed chromatin, and inconspicuous nucleoli (H&E, 
×20). (D) Hypercellular area containing plump mononuclear 
cells resembling chondroblasts, and admixed with multinucle-
ated giant cells resembling osteoclasts (H&E, ×40).
Table 3: Immunohistochemistry results of the three cases of chondromyxoid fibromas
Antibody Case no. 1 Case no. 2 Case no. 3 Case no. 4
S-100 Negative Negative Negative Negative
SMA Negative Negative Positive Positive
AE1-AE3 Negative Negative Negative Negative
EMA Negative Negative Negative Negative
CD34 Negative Negative Negative Negative
Ki-67 < 5% < 5% < 5% < 5%Diagnostic Pathology 2007, 2:44 http://www.diagnosticpathology.org/content/2/1/44
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cal distinguishing features. Microscopic calcification is
found in about 20% of cases [39]. However, they rarely
show calcification on plain X-rays, and are less likely to be
confused radiologically with chondroblastomas, enchon-
dromas, or low-grade chondrosarcomas [23,24]. Wilson
and colleagues observed that the difficulties with the radi-
ological diagnosis of CMF resulted more from the diver-
sity of sites of involvement and its relative rarity rather
than from its radiographic features [23].
CMF rarely arises within the ribs [7,18-22], with only
seven cases described so far. The tumor we describe in the
rib is histologically typical CMF, with low proliferative Ki-
67 index and almost total absence of mitotic activity, but
it is unusual not only because of the location and size, but
also because of the novel chromosomal translocation
found herein and the additional non-clonal random chro-
mosomal aberrations. The latter might be indicative of
genetic instability [40] and may reflect on its large size,
though this is speculative. There is the need to identify
genetic or molecular markers that can aid in confirming
the histological impression. Cytogenetic studies of CMF
are limited, with 15 previously reported cases in the Eng-
lish language medical literature [29-38]. In the 15 previ-
ously reported cases, the tumor was shown to be diploid,
with the most common recurring clonal abnormalities
involving chromosome 6. In particular, rearrangement of
the long arm of chromosome 6 at bands q13 and q25 was
most frequent [29-38]. Bridge and Tarkannen both
described cases of CMF with aberrations in chromosomes
2 and 5 [29,38], and Ozaki [34] described a case with a
gain involving 13q and losses involving 1p, 12q, 16p,
17p, 19p, 19q, 20q, and 22q. The remaining 12 reported
cases demonstrated abnormalities in chromosome 6 [30-
33,35-37]. Four of these cases demonstrated a pericentric
inversion, inv(6)(p25q13) [32,35,36]. One other case
demonstrated a different pericentric inversion,
inv(6)(p25q23), and the remainder of the cases demon-
strated rearrangements in three distinct breakpoint cluster
regions, namely 6p23-p25, 6q12-q15, and 6q23-q27 [29-
38]. The cytogenetic findings in our case of the rib mass
(case no. 2) revealed clonal translocation t(1;5)(p13;p13)
and represents the first report of this clonal rearrangement
as the sole abnormality in CMF. Although structural chro-
mosomal aberrations involving 1p13 [41-43] and 5p13
[35,44] have been described in chondrosarcomas, these
have not been previously reported in CMF.
The morphologic features of CMF may mimic other carti-
lage-producing neoplasms, especially when occurring in
flat bones. Most importantly, CMF can be misdiagnosed
as a malignant tumor because of its variable histology,
occasional striking cytologic atypia, occasional soft tissue
extension, and recurrences. Because of the rarity of CMF,
little is known regarding its histogenesis, genetic and bio-
logic characteristics. Based on its variable immunostain-
ing for smooth muscle actin (SMA) and S-100, some
investigators have suggested that they are related to chon-
droblastoma, but CMF is thought to be far less aggressive
and considerably different histologically [5,7,9,12,26-28].
The chondroid areas of CMF showed S-100 immunoreac-
Karyotype of CMF of the right anterior second rib (case no.  2) Figure 6
Karyotype of CMF of the right anterior second rib (case no. 
2). International System for Human Cytogenetic Nomencla-
ture (ISCN 2005): 46,XX,t(1;5)(p13;p13) [18]/46,XX [3].
Immunohistochemical findings of CMF obtained curetted sur- gical specimen (case no. 3) Figure 5
Immunohistochemical findings of CMF obtained curetted sur-
gical specimen (case no. 3). (A) Negative immunostaining 
with S-100 (Immunoperoxidase, ×20). (B) Negative immu-
nostaining with AE1-AE3 (Immunoperoxidase, ×20). (C) Pos-
itive immunostaining of tumor cells with smooth muscle actin 
(SMA) [Immunoperoxidase, ×20]. (D) Tumor showed low 
proliferative index with Ki-67 labeling less than 10% of neo-
plastic cells (Immunoperoxidase, ×20).Diagnostic Pathology 2007, 2:44 http://www.diagnosticpathology.org/content/2/1/44
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tivity in greater than 70% of cases, but did not stain for
SMA. Conversely, the peripheral regions surrounding the
chondroid areas commonly showed SMA immunoreactiv-
ity, but did not stain for S-100 [5,26-28].
The purely histological differential diagnosis of CMF may
include chondroblastoma, fibrous dysplasia, chondro-
myxoma-like or chondroblastic variant of low-grade oste-
osarcoma, and high-grade myxoid chondrosarcoma [4,7-
10]. The distinction is important due to their different nat-
ural history, prognosis and management. The location,
age of the patient, and the radiological features are
extremely important in the diagnosis of majority of bone
neoplasms. Chondroid neoplasms of the small bones of
distal extremities are seldom malignant, and conversely
cartilagenous tumors occurring in the flat bones (includ-
ing ribs and pelvic bones) are more often malignant than
benign. To decrease the risk of diagnostic error, the path-
ological diagnosis of CMF must be established on the
basis of careful correlation of clinical, radiographic and
immunohistochemical findings [5,26-28,45]. Chondrob-
lastomas are epiphyseal, unlike CMF which are metaphy-
seal in location. Additionally, the chondroblasts in
chondroblastoma have eosinophilic, polygonal cyto-
plasm (not stellate as in CMF), and calcification is a con-
spicuous feature of most chondroblastomas, unlike CMF
[5,26-28,45]. Fibrous dysplasia may, at times, show
extreme myxoid change; however, the accompanying
presence of irregular osteoid seams and the radiological
appearance help to make the distinction from CMF [5,26-
28,45]. None of the four cases herein reviewed were mis-
diagnosed as any of the differential diagnosis of CMF
mentioned above. Immunohistochemistry is not helpful
in distinguishing chondrosarcoma from CMF because
both tumors are known to express vimentin and S-100
protein [5,26-28,45]. Chondromyxoma-like or chondrob-
lastic variant of low-grade osteosarcoma, which have very
large CMF-like areas, are difficult to differentiate from
CMF on a small biopsy. However, mitoses and nuclear
atypia, which are seen in osteosarcomas, are not the fea-
tures of CMF. The diagnostic hallmark of osteosarcoma is
the presence of osteoid production, which is totally lack-
ing in CMF [5,26-28,45].
Conclusion
CMF can and should be distinguished especially from
chondromyxoma-like or chondroblastic variant of low-
grade osteosarcoma and high-grade myxoid chondrosar-
coma, two tumors which are more frequently seen, more
aggressive and have the capacity to metastasize. Hence,
any lesion labeled as CMF is best confirmed and managed
in a specialty bone center, where clinical, radiological and
pathological correlation can be optimally achieved.
Although often difficult to diagnose, CMFs are relatively
easy to treat by curettage with bone grafting or "enbloc"
resection, with mininal risk of recurrence. The
t(1;5)(p13;p13) is a novel sole clonal cytogenetic abnor-
mality in CMF. Although cytogenetic studies of CMF have
not yet yielded a specific causative genetic abnormality,
cytogenetic analysis may be of value, and should be per-
formed in all cases of CMF with unusual or borderline
clinicopathological features.
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